Back to search
FDAFDA · Food and drugs·Recall number D-0702-2018

NEOstigmine Methylsulfate (1 mg/mL) 3mg per 3mL. 3mL Single Dose Syringe. Premier Pharmacy Labs. 8265 Commercial Way Weeki Wachee, FL 34613 NDC 69623-234-14.

Published May 2, 2018 · Recall initiated: April 11, 2018

Summary

FDA records drug Class II recall D-0702-2018, published May 2, 2018 and initiated April 11, 2018. Recalling firm: Premier Pharmacy Labs Inc; Status: Terminated; Reported quantity: 600 syringes; Lot: Lot: NEO022218SVDS BUD: 8/21/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility:Microbial contamination was detected during routine testing of subsequent unreleased product lots due to interaction between the product syringe and tamper evident container closure, which may result in the potential introduction of microorganisms into the products.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Premier Pharmacy Labs Inc
Distributor
Nationwide in the USA
Lot
Lot: NEO022218SVDS BUD: 8/21/2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was NEOstigmine Methylsulfate (1 mg/mL) 3mg per 3mL. 3mL Single Dose Syringe. Premier Pharmacy Labs. 8265 Commercial Way Weeki Wachee, FL 34613 NDC 69623-234-14. recalled?

Yes. FDA published recall D-0702-2018 on May 2, 2018. Reported hazard: Lack of Assurance of Sterility:Microbial contamination was detected during routine testing of subsequent unreleased product lots due to interaction between the product syringe and tamper evident container closure, which may result in the potential introduction of microorganisms into the products.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release